Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Lung Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 125 articles: HTML format

Single Articles

June 2020
1. ZHOU ZW, Ambrogio C, Bera AK, Li Q, et al
   KRASQ61H preferentially signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer.
   Cancer Res. 2020 Jun 30. pii: 0008-5472.CAN-20-0448.
   PubMed     Abstract available
   
   
   
2. YANG YC, Pan KF, Lee WJ, Chang JH, et al
   Circulating proteoglycan endocan mediates EGFR-driven progression of non-small cell lung cancer.
   Cancer Res. 2020 Jun 19. pii: 0008-5472.CAN-20-0005.
   PubMed     Abstract available
   
   
   April 2020
3. ZHAO H, Iqbal NJ, Sukrithan V, Nicholas C, et al
   Targeted inhibition of the E3 ligase SCF-Skp2/Cks1 has antitumor activity in RB1-deficient human and mouse small cell lung cancer (SCLC).
   Cancer Res. 2020 Apr 7. pii: 0008-5472.CAN-19-2400.
   PubMed     Abstract available
   
   
   March 2020
4. ZONG D, Gu J, Cavalcante GC, Yao W, et al
   BRD4 levels determine the response of human lung cancer cells to BET degraders that potently induce apoptosis through suppression of Mcl-1.
   Cancer Res. 2020 Mar 10. pii: 0008-5472.CAN-19-3674.
   PubMed     Abstract available
   
   
   January 2020
5. TAVERNA JA, Hung CN, DeArmond DT, Chen M, et al
   Single-cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
   Cancer Res. 2020 Jan 28. pii: 0008-5472.CAN-19-3183.
   PubMed     Abstract available
   
   
   
6. CRISTEA S, Coles GL, Hornburg D, Gershkovitz M, et al
   The MEK5-ERK5 kinase axis controls lipid metabolism in small cell lung cancer.
   Cancer Res. 2020 Jan 22. pii: 0008-5472.CAN-19-1027.
   PubMed     Abstract available
   
   
   
7. IKEMORI R, Gabasa M, Duch P, Vizoso M, et al
   Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma.
   Cancer Res. 2020;80:276-290.
   PubMed     Abstract available
   
   
   
8. WANG S, Rong R, Yang DM, Fujimoto J, et al
   Computational staining of pathology images to study the tumor microenvironment in lung cancer.
   Cancer Res. 2020 Jan 8. pii: 0008-5472.CAN-19-1629.
   PubMed     Abstract available
   
   
   November 2019
9. HAVEL JJ
   MEK Inhibitors in Lung Cancer-You Can Teach an Old Drug New Tricks.
   Cancer Res. 2019;79:5699-5701.
   PubMed     Abstract available
   
   
   
10. LOURENCO AR, Ban Y, Crowley MJ, Lee SB, et al
    Differential contributions of pre- and post- EMT tumor cells in breast cancer metastasis.
    Cancer Res. 2019 Nov 8. pii: 0008-5472.CAN-19-1427.
    PubMed     Abstract available
    
    
    October 2019
11. CHEN G, Park D, Magis AT, Behera M, et al
    Mcl-1 interacts with Akt to promote lung cancer progression.
    Cancer Res. 2019 Oct 29. pii: 0008-5472.CAN-19-0950.
    PubMed     Abstract available
    
    
    
12. CHIOU J, Chang YC, Tsai HF, Lin YF, et al
    Follistatin-like protein 1 inhibits lung cancer metastasis by preventing proteolytic activation of osteopontin.
    Cancer Res. 2019 Oct 25. pii: 0008-5472.CAN-19-0842.
    PubMed     Abstract available
    
    
    
13. BOWCOCK AM
    A Breath of Fresh Air: Opening up the Lung Cancer Genome.
    Cancer Res. 2019;79:4808-4810.
    PubMed     Abstract available
    
    
    
14. DONG SH, Li W, Wang L, Hu J, et al
    Histone-related genes are hypermethylated in lung cancer and hypermethylated HIST1H4F could serve as a pan-cancer biomarker.
    Cancer Res. 2019 Oct 1. pii: 0008-5472.CAN-19-1019.
    PubMed     Abstract available
    
    
    
15. MERRICK DT
    Sequencing the Events That Mediate Progression of Premalignant Lung Lesions.
    Cancer Res. 2019;79:4811-4813.
    PubMed     Abstract available
    
    
    
16. KRYSAN K, Tran LM, Grimes BS, Fishbein GA, et al
    The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.
    Cancer Res. 2019;79:5022-5033.
    PubMed     Abstract available
    
    
    September 2019
17. HO MY, Liang SM, Hung SW, Liang CM, et al
    Retraction: MIG-7 Controls COX-2/PGE2-Mediated Lung Cancer Metastasis.
    Cancer Res. 2019;79:4553.
    PubMed    
    
    
    August 2019
18. CHUANG HC, Chang CC, Teng CF, Hsueh CH, et al
    MAP4K3/GLK promotes lung cancer metastasis by phosphorylating and activating IQGAP1.
    Cancer Res. 2019 Aug 20. pii: 0008-5472.CAN-19-1402.
    PubMed     Abstract available
    
    
    
19. VARTANIAN S, Lee J, Klijn C, Gnad F, et al
    ERBB3 and IGF1R signaling are required for Nrf2-dependent growth in KEAP1-mutant lung cancer.
    Cancer Res. 2019 Aug 15. pii: 0008-5472.CAN-18-2086.
    PubMed     Abstract available
    
    
    July 2019
20. XIE M, Zheng H, Madan-Lala R, Dai W, et al
    MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer.
    Cancer Res. 2019 Jul 30. pii: 0008-5472.CAN-19-0698.
    PubMed     Abstract available
    
    
    
21. CHANG YC, Chiou J, Yang YF, Su CY, et al
    Therapeutic Targeting of Aldolase A Interactions Inhibits Lung Cancer Metastasis and Prolongs Survival.
    Cancer Res. 2019 Jul 29. pii: 0008-5472.CAN-18-4080.
    PubMed     Abstract available
    
    
    
22. ZHENG ZQ, Li ZX, Zhou GQ, Lin L, et al
    Long non-coding RNA FAM225A promotes nasopharyngeal carcinoma tumorigenesis and metastasis by acting as ceRNA to sponge miR-590-3p/miR-1275 and upregulate ITGB3.
    Cancer Res. 2019 Jul 22. pii: 0008-5472.CAN-19-0799.
    PubMed     Abstract available
    
    
    June 2019
23. KAMAL Y, Schmit SL, Hoehn HJ, Amos CI, et al
    Transcriptomic differences between primary colorectal adenocarcinomas and distant metastases reveal metastatic colorectal cancer subtypes.
    Cancer Res. 2019 Jun 25. pii: 0008-5472.CAN-18-3945.
    PubMed     Abstract available
    
    
    
24. ACHARYA S, Yao J, Li P, Zhang C, et al
    Sphingosine-kinase-1 signaling promotes metastasis of triple-negative breast cancer.
    Cancer Res. 2019 Jun 25. pii: 0008-5472.CAN-18-3803.
    PubMed     Abstract available
    
    
    
25. WANG Z, Tu K, Xia L, Luo K, et al
    The Open Chromatin Landscape of Non-small Cell Lung Carcinoma.
    Cancer Res. 2019 Jun 17. pii: 0008-5472.CAN-18-3663.
    PubMed     Abstract available
    
    
    
26. DAVALOS V, Esteller M
    Disruption of Long Noncoding RNAs Targets Cancer Hallmark Pathways in Lung Tumorigenesis.
    Cancer Res. 2019;79:3028-3030.
    PubMed     Abstract available
    
    
    
27. SHAHABI S, Kumaran V, Castillo J, Cong Z, et al
    LINC00261 Is an Epigenetically Regulated Tumor Suppressor Essential for Activation of the DNA Damage Response.
    Cancer Res. 2019;79:3050-3062.
    PubMed     Abstract available
    
    
    May 2019
28. SASAKI Y, Fujimori H, Hozumi M, Onodera T, et al
    Dysfunction of poly(ADP-ribose) glycohydrolase induces a synthetic lethal effect in dual specificity phosphatase 22-deficient lung cancer cells.
    Cancer Res. 2019 May 29. pii: 0008-5472.CAN-18-1037.
    PubMed     Abstract available
    
    
    
29. SONG M, Ping Y, Zhang K, Yang L, et al
    Low-dose IFN-gamma induces tumor cell stemness in the tumor microenvironment of non-small cell lung cancer.
    Cancer Res. 2019 May 13. pii: 0008-5472.CAN-19-0596.
    PubMed     Abstract available
    
    
    April 2019
30. KONDO Y
    Genome-Epigenome-Senescence: Is TET1 a Caretaker of p53-Injured Lung Cancer Cells?
    Cancer Res. 2019;79:1751-1752.
    PubMed     Abstract available
    
    
    
31. PAIDI SK, Diaz PM, Dadgar S, Jenkins SV, et al
    Label-Free Raman Spectroscopy Reveals Signatures of Radiation Resistance in the Tumor Microenvironment.
    Cancer Res. 2019;79:2054-2064.
    PubMed     Abstract available
    
    
    
32. BUSHNELL GG, Hardas TP, Hartfield RM, Zhang Y, et al
    Biomaterial Scaffolds Recruit an Aggressive Population of Metastatic Tumor Cells In Vivo.
    Cancer Res. 2019;79:2042-2053.
    PubMed     Abstract available
    
    
    
33. LEWIS DM, Pruitt H, Jain N, Ciccaglione M, et al
    A Feedback Loop between Hypoxia and Matrix Stress Relaxation Increases Oxygen-Axis Migration and Metastasis in Sarcoma.
    Cancer Res. 2019;79:1981-1995.
    PubMed     Abstract available
    
    
    
34. ZHAO J, Feng M, Liu D, Liu H, et al
    Antagonism between HtrA3 and TGF-beta1 Contributes to Metastasis in Non-small-cell Lung Cancer.
    Cancer Res. 2019 Apr 2. pii: 0008-5472.CAN-18-2507.
    PubMed     Abstract available
    
    
    
35. RAMAMOORTHY P, Thomas SM, Kaushik G, Subramaniam D, et al
    Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response.
    Cancer Res. 2019;79:1681-1695.
    PubMed     Abstract available
    
    
    
36. VUONG L, Kouverianou E, Rooney CM, McHugh BJ, et al
    An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.
    Cancer Res. 2019;79:1480-1492.
    PubMed     Abstract available
    
    
    March 2019
37. SOHONI S, Ghosh P, Wang T, Kalainayakan SP, et al
    Elevated heme synthesis and uptake underpin intensified oxidative metabolism and tumorigenic functions in non-small cell lung cancer cells.
    Cancer Res. 2019 Mar 22. pii: 0008-5472.CAN-18-2156.
    PubMed     Abstract available
    
    
    
38. ZOU T, Meyerson M
    Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer.
    Cancer Res. 2019;79:1038-1040.
    PubMed     Abstract available
    
    
    
39. UDYAVAR AR, Wooten DJ, Hoeksema M, Bansal M, et al
    Correction: Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity.
    Cancer Res. 2019;79:1014.
    PubMed    
    
    
    February 2019
40. HALLAHAN D
    ATM Inhibition Sensitizes Tumors to High-Dose Irradiation.
    Cancer Res. 2019;79:704-705.
    PubMed     Abstract available
    
    
    
41. FUKUDA K, Takeuchi S, Arai S, Katayama R, et al
    Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status.
    Cancer Res. 2019 Feb 8. pii: 0008-5472.CAN-18-2052.
    PubMed     Abstract available
    
    
    
42. YAN Y, Sun N, Wang H, Kobayashi M, et al
    Whole genome-derived tiled peptide arrays detect pre-diagnostic autoantibody signatures in non-small cell lung cancer.
    Cancer Res. 2019 Feb 5. pii: 0008-5472.CAN-18-1536.
    PubMed     Abstract available
    
    
    
43. MURTUZA A, Bulbul A, Shen JP, Keshavarzian P, et al
    Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.
    Cancer Res. 2019 Feb 4. pii: 0008-5472.CAN-18-1281.
    PubMed     Abstract available
    
    
    
44. ROMAN M, Lopez I, Guruceaga E, Baraibar I, et al
    Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.
    Cancer Res. 2019;79:625-638.
    PubMed     Abstract available
    
    
    
45. NEEL DS, Allegakoen DV, Olivas V, Mayekar MK, et al
    Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
    Cancer Res. 2019;79:546-556.
    PubMed     Abstract available
    
    
    January 2019
46. LI YP, Sin TK, Zhu JZ, Zhang G, et al
    p300 mediates muscle wasting in Lewis lung carcinoma.
    Cancer Res. 2019 Jan 31. pii: 0008-5472.CAN-18-1653.
    PubMed     Abstract available
    
    
    
47. JIANG Y, Chen T, Wang T, Liang W, et al
    PAK4 phosphorylates fumarase and blocks TGF-beta-induced cell growth arrest in lung cancer cells.
    Cancer Res. 2019 Jan 25. pii: 0008-5472.CAN-18-2575.
    PubMed     Abstract available
    
    
    
48. SHIELDS BD, Koss B, Taylor EM, Storey AJ, et al
    Loss of E-cadherin inhibits CD103 anti-tumor activity and reduces checkpoint blockade responsiveness in melanoma.
    Cancer Res. 2019 Jan 23. pii: 0008-5472.CAN-18-1722.
    PubMed     Abstract available
    
    
    
49. DYER A, Schoeps B, Frost S, Jakeman P, et al
    Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.
    Cancer Res. 2019;79:331-345.
    PubMed     Abstract available
    
    
    
50. FILIPCZAK PT, Leng S, Tellez CS, Do KC, et al
    p53-suppressed oncogene TET1 prevents cellular aging in lung cancer.
    Cancer Res. 2019 Jan 8. pii: 0008-5472.CAN-18-1234.
    PubMed     Abstract available
    
    
    
51. KOSSENKOV AV, Qureshi R, Dawany NB, Wickramasinghe J, et al
    A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.
    Cancer Res. 2019;79:263-273.
    PubMed     Abstract available
    
    
    
52. WERFEL TA, Elion DL, Rahman B, Hicks DJ, et al
    Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.
    Cancer Res. 2019;79:171-182.
    PubMed     Abstract available
    
    
    
53. YAN X, Zhang X, Wang L, Zhang R, et al
    Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.
    Cancer Res. 2019;79:125-132.
    PubMed     Abstract available
    
    
    December 2018
54. PHALLEN J, Leal A, Woodward BD, Forde PM, et al
    Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer.
    Cancer Res. 2018 Dec 20. pii: 0008-5472.CAN-18-1082.
    PubMed     Abstract available
    
    
    
55. ANAGNOSTOU V, Forde PM, White JR, Niknafs N, et al
    Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer.
    Cancer Res. 2018 Dec 12. pii: 0008-5472.CAN-18-1127.
    PubMed     Abstract available
    
    
    November 2018
56. LAN J, Sun L, Xu F, Liu L, et al
    M2 macrophage-derived exosomes promote cell migration and invasion in colon cancer.
    Cancer Res. 2018 Nov 6. pii: 0008-5472.CAN-18-0014.
    PubMed     Abstract available
    
    
    
57. WANG J, Wang D, Niu X, Wang Z, et al
    Multiregion sequencing reveals the genetic heterogeneity and evolutionary history of osteosarcoma and matched pulmonary metastases.
    Cancer Res. 2018 Nov 2. pii: 0008-5472.CAN-18-1086.
    PubMed     Abstract available
    
    
    October 2018
58. EL KADI N, Wang L, Davis A, Korkaya H, et al
    The EGFR T790M mutation is acquired through AICDA-mediated deamination of 5-methylcytosine following TKI treatment in lung cancer.
    Cancer Res. 2018 Oct 17. pii: 0008-5472.CAN-17-3370.
    PubMed     Abstract available
    
    
    August 2018
59. HUANG F, Shi Q, Li Y, Xu L, et al
    HER2/EGFR-AKT signaling switches TGF-beta from inhibiting cell proliferation to promoting cell migration in breast cancer.
    Cancer Res. 2018 Aug 31. pii: 0008-5472.CAN-18-0136.
    PubMed     Abstract available
    
    
    
60. ZHOU Y, Shurin GV, Zhong H, Bunimovich YL, et al
    Schwann cells augment cell spreading and metastasis of lung cancer.
    Cancer Res. 2018 Aug 22. pii: 0008-5472.CAN-18-1702.
    PubMed     Abstract available
    
    
    
61. MARTIN-SANCHEZ JC, Lunet N, Gonzalez-Marron A, Lidon-Moyano C, et al
    Projections in Breast and Lung Cancer Mortality among Women: A Bayesian Analysis of 52 Countries Worldwide.
    Cancer Res. 2018;78:4436-4442.
    PubMed     Abstract available
    
    
    June 2018
62. BROUWER AF, Eisenberg MC, Meza R
    Case Studies of Gastric, Lung, and Oral Cancer Connect Etiologic Agent Prevalence to Cancer Incidence.
    Cancer Res. 2018;78:3386-3396.
    PubMed     Abstract available
    
    
    May 2018
63. MEDER L, Schuldt P, Thelen M, Schmitt A, et al
    Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer.
    Cancer Res. 2018 May 18. pii: 0008-5472.CAN-17-2176.
    PubMed     Abstract available
    
    
    April 2018
64. HEIM L, Friedrich J, Engelhardt M, Trufa DI, et al
    NFATc1 promotes anti-tumoral effector functions and memory CD8+ T cell differentiation during non-small cell lung cancer development.
    Cancer Res. 2018 Apr 24. pii: 0008-5472.CAN-17-3297.
    PubMed     Abstract available
    
    
    
65. SU W, Feng S, Chen X, Yang X, et al
    Silencing of long non-coding RNA MIR22HG triggers cell survival/death signaling via oncogenes YBX1, MET, and p21 in lung cancer.
    Cancer Res. 2018 Apr 18. pii: 0008-5472.CAN-18-0222.
    PubMed     Abstract available
    
    
    
66. LU YX, Ju HQ, Liu ZX, Chen DL, et al
    ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis.
    Cancer Res. 2018;78:1972-1985.
    PubMed     Abstract available
    
    
    March 2018
67. SILINA K, Soltermann A, Attar FM, Casanova R, et al
    Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
    Cancer Res. 2018;78:1308-1320.
    PubMed     Abstract available
    
    
    February 2018
68. MAKINOSHIMA H, Umemura S, Suzuki A, Nakanishi H, et al
    Metabolic determinants of sensitivity to phosphatidylinositol 3-kinase pathway inhibitor in small-cell lung carcinoma.
    Cancer Res. 2018 Feb 28. pii: 0008-5472.CAN-17-2109.
    PubMed     Abstract available
    
    
    
69. DE S, Lindner DJ, Coleman C, Wildey G, et al
    The FACT inhibitor CBL0137 synergizes with cisplatin in small cell lung cancer by increasing NOTCH1 expression and targeting tumor-initiating cells.
    Cancer Res. 2018 Feb 13. pii: 0008-5472.CAN-17-1920.
    PubMed     Abstract available
    
    
    January 2018
70. CARONNI N, Simoncello F, Stafetta F, Guarnaccia C, et al
    Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer.
    Cancer Res. 2018 Jan 23. pii: 0008-5472.CAN-17-1307.
    PubMed     Abstract available
    
    
    
71. DOPESO H, Jiao HK, Cuesta AM, Henze AT, et al
    PHD3 controls lung cancer metastasis and resistance to EGFR inhibitors through TGFalpha.
    Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-1346.
    PubMed     Abstract available
    
    
    
72. YANG Y, Leonard M, Zhang Y, Zhao D, et al
    HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1.
    Cancer Res. 2018;78:422-435.
    PubMed     Abstract available
    
    
    
73. TIMANER M, Letko-Khait N, Kotsofruk R, Benguigui M, et al
    Therapy-educated mesenchymal stem cells enrich for tumor initiating cells.
    Cancer Res. 2018 Jan 4. pii: 0008-5472.CAN-17-1547.
    PubMed     Abstract available
    
    
    
74. ARNST KE, Wang Y, Hwang DJ, Xue Y, et al
    A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Cancer Res. 2018;78:265-277.
    PubMed     Abstract available
    
    
    December 2017
75. ADELAIYE-OGALA R, Budka J, Damayanti NP, Arrington J, et al
    EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.
    Cancer Res. 2017;77:6651-6666.
    PubMed     Abstract available
    
    
    November 2017
76. EMERSON MA, Banegas MP, Chawla N, Achacoso N, et al
    Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0429.
    PubMed     Abstract available
    
    
    
77. HOU P, Li L, Chen F, Chen Y, et al
    PTBP3-mediated regulation of ZEB1 mRNA stability promotes epithelial-mesenchymal transition in breast cancer.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0883.
    PubMed     Abstract available
    
    
    
78. BYRD TT, Fousek K, Pignata A, Szot C, et al
    TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer.
    Cancer Res. 2017 Nov 28. pii: 0008-5472.CAN-16-1911.
    PubMed     Abstract available
    
    
    
79. SIVAKUMAR S, Lucas FAS, McDowell TL, Lang W, et al
    Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.
    Cancer Res. 2017;77:6119-6130.
    PubMed     Abstract available
    
    
    
80. KWAK JW, Laskowski J, Li HY, McSharry MV, et al
    Complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression.
    Cancer Res. 2017 Nov 8. pii: canres.0240.2017.
    PubMed     Abstract available
    
    
    
81. WANG W, Huang L, Jin JY, Jolly S, et al
    IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.
    Cancer Res. 2017 Nov 8. pii: canres.2995.2017.
    PubMed     Abstract available
    
    
    
82. HUANG H, Zhang W, Pan Y, Gao Y, et al
    YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation.
    Cancer Res. 2017;77:5769-5781.
    PubMed     Abstract available
    
    
    
83. HUA KT, Hong JB, Sheen YS, Huang HY, et al
    MicroRNA-519d promotes melanoma progression by downregulating EphA4.
    Cancer Res. 2017 Nov 1. pii: canres.1933.2017.
    PubMed     Abstract available
    
    
    October 2017
84. ZUO H, Ueland PM, Midttun O, Vollset SE, et al
    Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) link vitamin B6 catabolism and lung cancer risk.
    Cancer Res. 2017 Oct 25. pii: canres.1923.2017.
    PubMed     Abstract available
    
    
    September 2017
85. KIDDER BL, He R, Wangsa D, Padilla-Nash HM, et al
    SMYD5 controls heterochromatin and chromosome integrity during embryonic stem cell differentiation.
    Cancer Res. 2017 Sep 26. pii: canres.0828.2017.
    PubMed     Abstract available
    
    
    
86. SHUKLA V, Rao M, Zhang H, Beers J, et al
    ASXL3 is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer.
    Cancer Res. 2017 Sep 21. pii: canres.0570.2017.
    PubMed     Abstract available
    
    
    
87. YAO M, Yu T, Zhao YJ, Hu Z, et al
    MetaLnc9 facilitates lung cancer metastasis via a PGK1-activated AKT/mTOR pathway.
    Cancer Res. 2017 Sep 18. pii: canres.0671.2017.
    PubMed     Abstract available
    
    
    
88. LIU Y, Li Y, Wang X, Liu F, et al
    Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
    Cancer Res. 2017;77:5068-5076.
    PubMed     Abstract available
    
    
    
89. MURLIDHAR V, Reddy RM, Fouladdel S, Zhao L, et al
    Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers.
    Cancer Res. 2017;77:5194-5206.
    PubMed     Abstract available
    
    
    
90. MCFARLAND CD, Yaglom JA, Wojtkowiak JW, Scott JG, et al
    The Damaging Effect of Passenger Mutations on Cancer Progression.
    Cancer Res. 2017;77:4763-4772.
    PubMed     Abstract available
    
    
    
91. KACHLER K, Bailer M, Heim L, Schumacher F, et al
    Enhanced acid sphingomyelinase activity drives immune evasion and tumor growth in non-small cell lung carcinoma.
    Cancer Res. 2017 Sep 7. pii: canres.3313.2016.
    PubMed     Abstract available
    
    
    
92. TAKAGI S, Ishikawa Y, Mizutani A, Iwasaki S, et al
    LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
    Cancer Res. 2017;77:4652-4662.
    PubMed     Abstract available
    
    
    August 2017
93. KASIRI S, Shao C, Chen B, Wilson AN, et al
    GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.
    Cancer Res. 2017;77:4448-4459.
    PubMed     Abstract available
    
    
    July 2017
94. TILL J, Yoon C, Kim BJ, Roby KC, et al
    Oncogenic KRAS and p53 loss drive gastric tumorigenesis in mice that can be attenuated by E-cadherin expression.
    Cancer Res. 2017 Jul 31. pii: canres.0061.2017.
    PubMed     Abstract available
    
    
    
95. DU W, Xu X, Niu Q, Zhang X, et al
    Spi-B-mediated silencing of Claudin-2 promotes early dissemination of lung cancer cells from primary tumors.
    Cancer Res. 2017 Jul 28. pii: canres.0020.2017.
    PubMed     Abstract available
    
    
    
96. SALVADOR F, Martin A, Lopez-Menendez C, Moreno-Bueno G, et al
    Lysyl oxidase-like protein LOXL2 promotes lung metastasis of breast cancer.
    Cancer Res. 2017 Jul 18. pii: canres.3152.2016.
    PubMed     Abstract available
    
    
    
97. COOPER JM, Ou YH, McMillan E, Vaden RM, et al
    TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer.
    Cancer Res. 2017 Jul 17. pii: canres.0829.2017.
    PubMed     Abstract available
    
    
    
98. JERMYN M, Mercier J, Aubertin K, Desroches J, et al
    Highly Accurate Detection of Cancer In Situ with Intraoperative, Label-Free, Multimodal Optical Spectroscopy.
    Cancer Res. 2017;77:3942-3950.
    PubMed     Abstract available
    
    
    
99. JIANG H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, et al
    Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
    Cancer Res. 2017;77:3894-3907.
    PubMed     Abstract available
    
    
    
100. CHAKRABARTI S, Michor F
     Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution.
     Cancer Res. 2017;77:3908-3921.
     PubMed     Abstract available
     
     
     
101. NG KY, Chan LH, Chai S, Tong M, et al
     TP53INP1 down-regulation activates a p73-dependent DUSP10/ERK signaling pathway to promote metastasis of hepatocellular carcinoma.
     Cancer Res. 2017 Jul 3. pii: canres.3456.2016.
     PubMed     Abstract available
     
     
     June 2017
102. RICHER AL, Cala JM, O'Brien K, Carson VM, et al
     WEE1 kinase inhibitor AZD1775 has pre-clinical efficacy in LKB1-deficient non-small cell lung cancer.
     Cancer Res. 2017 Jun 26. pii: canres.3565.2016.
     PubMed     Abstract available
     
     
     
103. YOUNG A, Ngiow SF, Madore J, Reinhardt J, et al
     Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis.
     Cancer Res. 2017 Jun 26. pii: canres.0393.2017.
     PubMed     Abstract available
     
     
     
104. TRIPATHI SC, Fahrmann JF, Celiktas M, Aguilar M, et al
     MCAM mediates chemoresistance in small cell lung cancer via the PI3K/AKT/SOX2 signaling pathway.
     Cancer Res. 2017 Jun 23. pii: canres.2874.2016.
     PubMed     Abstract available
     
     
     May 2017
105. RIOS VELAZQUEZ E, Parmar C, Liu Y, Coroller TP, et al
     Somatic mutations drive distinct imaging phenotypes in lung cancer.
     Cancer Res. 2017 May 31. pii: canres.0122.2017.
     PubMed     Abstract available
     
     
     
106. YE M, Zhang Y, Zhang X, Zhang JB, et al
     Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer.
     Cancer Res. 2017 May 18. pii: canres.3470.2016.
     PubMed     Abstract available
     
     
     
107. SEN T, Tong P, Stewart CA, Cristea S, et al
     CHK1 inhibition in small cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib.
     Cancer Res. 2017 May 10. pii: canres.3409.2016.
     PubMed     Abstract available
     
     
     
108. PRAT A, Navarro A, Pare L, Reguart N, et al
     Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma.
     Cancer Res. 2017 May 9. pii: canres.3556.2017.
     PubMed     Abstract available
     
     
     
109. SHARMA SK, Pourat J, Abdel-Atti D, Carlin SD, et al
     Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
     Cancer Res. 2017 May 9. pii: canres.0299.2017.
     PubMed     Abstract available
     
     
     
110. PAILLER E, Oulhen M, Borget I, Remon J, et al
     Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients.
     Cancer Res. 2017;77:2222-2230.
     PubMed     Abstract available
     
     
     April 2017
111. ICHIHARA E, Westover D, Meador CB, Yan Y, et al
     SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer.
     Cancer Res. 2017 Apr 17. pii: canres.2300.2016.
     PubMed     Abstract available
     
     
     
112. ZHANG Y, Xu W, Guo H, Zhang Y, et al
     NOTCH1 Signaling Regulates Self-renewal and Platinum Chemoresistance of Cancer Stem-like Cells in Human Non-small Cell Lung Cancer.
     Cancer Res. 2017 Apr 17. pii: canres.1633.2016.
     PubMed     Abstract available
     
     
     
113. STEVENS LE, Cheung WKC, Adua SJ, Arnal-Estape A, et al
     Extracellular Matrix Receptor Expression in Subtypes of Lung Adenocarcinoma Potentiates Outgrowth of Micrometastases.
     Cancer Res. 2017;77:1905-1917.
     PubMed     Abstract available
     
     
     
114. WEN H, Chiu YF, Kuo MH, Lee KL, et al
     Expression of neuroendocrine factor VGF in lung cancer cells confers resistance to EGFR kinase inhibitors and triggers epithelial-to-mesenchymal transition.
     Cancer Res. 2017 Apr 5. pii: canres.3168.2016.
     PubMed     Abstract available
     
     
     
115. WALTER DM, Venancio OS, Buza EL, Tobias JW, et al
     Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma.
     Cancer Res. 2017;77:1719-1729.
     PubMed     Abstract available
     
     
     March 2017
116. LIAO L, Song M, Li X, Tang L, et al
     E3 ubiquitin ligase UBR5 drives the growth and metastasis of triple negative breast cancer.
     Cancer Res. 2017 Mar 22. pii: canres.2409.2016.
     PubMed     Abstract available
     
     
     January 2017
117. HAN SY, Ko A, Kitano H, Choi CH, et al
     Molecular Chaperone HSP90 Is Necessary to Prevent Cellular Senescence via Lysosomal Degradation of p14ARF.
     Cancer Res. 2017;77:343-354.
     PubMed     Abstract available
     
     
     
118. KAUFMAN JM, Yamada T, Park K, Timmers CD, et al
     A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.
     Cancer Res. 2017;77:153-163.
     PubMed     Abstract available
     
     
     
119. ZHOU X, Updegraff BL, Guo Y, Peyton M, et al
     PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.
     Cancer Res. 2017;77:187-197.
     PubMed     Abstract available
     
     
     
120. MAMAN S, Sagi-Assif O, Yuan W, Ginat R, et al
     The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis.
     Cancer Res. 2017;77:14-26.
     PubMed     Abstract available
     
     
     November 2016
121. DOWER CM, Bhat N, Wang EW, Wang HG, et al
     Selective Reversible Inhibition of Autophagy in Hypoxic Breast Cancer Cells Promotes Pulmonary Metastasis.
     Cancer Res. 2016 Nov 15. doi: 10.1158/0008-5472.CAN-15-3458.
     PubMed     Abstract available
     
     
     
122. PAIDI SK, Rizwan A, Zheng C, Cheng M, et al
     Label-Free Raman Spectroscopy Detects Stromal Adaptations in Premetastatic Lungs Primed by Breast Cancer.
     Cancer Res. 2016 Nov 15. doi: 10.1158/0008-5472.CAN-16-1862.
     PubMed     Abstract available
     
     
     August 2016
123. YOLDI G, Pellegrini P, Trinidad EM, Cordero A, et al
     RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation.
     Cancer Res. 2016 Aug 1. pii: canres.2745.2015.
     PubMed     Abstract available
     
     
     April 2016
124. BOUTET M, Gauthier L, Leclerc M, Gros G, et al
     TGFbeta Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment.
     Cancer Res. 2016;76:1757-69.
     PubMed     Abstract available
     
     
     
125. FUCIKOVA J, Becht E, Iribarren K, Goc J, et al
     Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.
     Cancer Res. 2016;76:1746-56.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: